Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1998;29:2261-2267

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kristensen, B.
Right arrow Articles by Olsson, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kristensen, B.
Right arrow Articles by Olsson, T.

(Stroke. 1998;29:2261-2267.)
© 1998 American Heart Association, Inc.


Original Contributions

Increased Fibrinogen Levels and Acquired Hypofibrinolysis in Young Adults With Ischemic Stroke

Bo Kristensen, MD, PhD; Jan Malm, MD, PhD; Torbjörn K. Nilsson, MD, PhD; Johan Hultdin, MD; Bo Carlberg, MD, PhD; Tommy Olsson, MD, PhD

From the Departments of Clinical Neuroscience (B.K., J.M.), Clinical Chemistry (T.K.N., J.H.), and Medicine (B.C., T.O.), University Hospital of Umeå (Sweden).

Correspondence to Bo Kristensen, MD, PhD, Department of Clinical Neuroscience, University Hospital, S-901 85 Umeå, Sweden. E-mail Bo.Kristensen{at}neuro.umu.se

Background and Purpose—Elevated fibrinogen levels and abnormalities in the fibrinolytic system are related to the occurrence of cardiovascular events. However, the role of these factors in the evolution of cerebrovascular disease has received less attention, in particular in young stroke patients. The aim of this study was to evaluate possible abnormalities in plasma fibrinogen levels and the state of the fibrinolytic system in young adults with a first-ever ischemic stroke.

Methods—This study is based on 102 consecutive patients aged 18 to 44 years admitted between January 1991 and May 1996 as a result of a first ischemic stroke. Forty-one healthy controls were recruited. Evaluations of anthropometric/metabolic variables, plasma fibrinogen levels, and the fibrinolytic system were undertaken >=3 months (mean, 5.4±2.0 months) after admission.

Results—Patients had lower tissue plasminogen activator activity and increased plasminogen activator inhibitor type 1 activity at baseline, as well as increased tissue plasminogen activator mass concentration both at baseline and after a venous occlusion test. Overall, there were no significant differences between the main etiologic subgroups regarding plasma fibrinogen levels and fibrinolytic variables. Baseline fibrinolytic variables were strongly correlated with body mass index, serum triglycerides, and cholesterol levels. After adjustments in multivariate models, fibrinogen levels and tissue plasminogen activator mass concentration both at baseline and after venous occlusion test remained significantly increased in patients. Logistic multiple regression analyses indicated that plasma fibrinogen was a strong predictor of ischemic stroke (odds ratio, 11.25; 95% CI, 3.27 to 38.69).

Conclusions—Increased fibrinogen levels and tissue plasminogen activator mass concentration are independently associated with ischemic stroke in young adults. Metabolic perturbations are closely interrelated with aberrations in tissue plasminogen activator and plasminogen activator inhibitor type 1 activity in these patients, findings consistent with an acquired hypofibrinolysis.


Key Words: fibrinogen • fibrinolysis • plasminogen activators • stroke, ischemic • young adults




This article has been cited by other articles:


Home page
StrokeHome page
K. Jood, P. Ladenvall, A. Tjarnlund-Wolf, C. Ladenvall, M. Andersson, S. Nilsson, C. Blomstrand, and C. Jern
Fibrinolytic Gene Polymorphism and Ischemic Stroke
Stroke, October 1, 2005; 36(10): 2077 - 2081.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Jannes, M. A. Hamilton-Bruce, L. Pilotto, B. J. Smith, C. G. Mullighan, P. G. Bardy, and S. A. Koblar
Tissue Plasminogen Activator -7351C/T Enhancer Polymorphism Is a Risk Factor for Lacunar Stroke
Stroke, May 1, 2004; 35(5): 1090 - 1094.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Martiskainen, T. Pohjasvaara, J. Mikkelsson, R. Mantyla, T. Kunnas, P. Laippala, E. Ilveskoski, M. Kaste, P.J. Karhunen, and T. Erkinjuntti
Fibrinogen Gene Promoter -455 A Allele as a Risk Factor for Lacunar Stroke
Stroke, April 1, 2003; 34(4): 886 - 891.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
L. Johansson, J.-H. Jansson, K. Boman, T. K. Nilsson, B. Stegmayr, and G. Hallmans
Tissue Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex as Risk Factors for the Development of a First Stroke
Stroke, January 1, 2000; 31(1): 26 - 32.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. Jaillard, C. Cornu, A. Durieux, T. Moulin, F. Boutitie, K. R. Lees, and M. Hommel
Hemorrhagic Transformation in Acute Ischemic Stroke : The MAST-E Study
Stroke, July 1, 1999; 30(7): 1326 - 1332.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. Kristensen, J. Malm, T. K. Nilsson, J. Hultdin, B. Carlberg, G. Dahlen, and T. Olsson
Hyperhomocysteinemia and Hypofibrinolysis in Young Adults With Ischemic Stroke
Stroke, May 1, 1999; 30(5): 974 - 980.
[Abstract] [Full Text] [PDF]